de Crombrugghe B, Katzenstein P, Mukhopadhyay K, Lefebvre V, Zhou G, Garofalo S, Metsäranta M, Rosati R, Vuorio E
M.D. Anderson Cancer Center, Department of Molecular Genetics, University of Texas, Houston 77030, USA.
J Rheumatol Suppl. 1995 Feb;43:140-2.
We address three issues that are important when considering somatic gene therapy approaches to osteoarthritis (OA) and related syndromes. First, only those diseases for which a precise molecular etiology has been established should be contemplated for somatic gene therapy. Second, DNA sequences should be identified that restrict expression of correcting genes to chondrocytes; we discuss the use of transgenic mice to identify such sequences. Third, we emphasize the usefulness of establishing animal models that mimic human OA syndromes by genetic manipulations. These transgenic models should be essential for testing gene therapy approaches in vivo.
我们探讨了在考虑采用体细胞基因治疗方法治疗骨关节炎(OA)及相关综合征时重要的三个问题。第一,体细胞基因治疗应仅考虑那些已明确精确分子病因的疾病。第二,应鉴定出能将矫正基因的表达限制于软骨细胞的DNA序列;我们讨论了利用转基因小鼠来鉴定此类序列。第三,我们强调通过基因操作建立模拟人类OA综合征的动物模型的有用性。这些转基因模型对于在体内测试基因治疗方法应是必不可少的。